Paladin Labs - Top Performer - Solide und viel Phantasie! - 500 Beiträge pro Seite

[Macos]

Neue Technologie einverleibt, Aktienrückkaufprogramm, einfach der Hammer!

Hier kann man glaube ich gar nicht verlieren. das ist Morphosys verdächtig? Sichere Gewinne und Milliarden potential?


Paladin Labs is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market Strong revenue growth • 5 year CAGR revenue growth of 21% Healthy, robust business • Generated $19.9 million of EBITDA in 2007 or $1.30 per share Rich, near-term pipeline for growth • 1 product awaiting regulatory approval • 8 products in phase I, II and III

von der Homepage!!http://www.paladin-labs.com/forinvestors/presentations.html" target="_blank" rel="nofollow ugc noopener">http://www.paladin-labs.com/forinvestors/presentations.html


Ich wünsche viel Freude mit Diesem Investment.

Gruss macos

[Macos]

http://www.paladin-labs.com/forinvestors/presentations.html

[Macos]

feine Zahlen



Press Release Source: Paladin Labs Inc.


Paladin Reports Record 2008 Fourth Quarter and Year End Results
Thursday February 26, 7:30 am ET
Company Provides 2009 Guidance


MONTREAL, CANADA--(Marketwire - Feb. 26, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, today reported its financial results for the fourth quarter and year ended December 31, 2008. The Company achieved record revenues for the fourth quarter of 2008 and has achieved its 13th consecutive year of record revenues.
ADVERTISEMENT


2008 Highlights

- Revenues for 2008 totaled a record $82.7 million, a 31% increase compared to 2007

- Sales of key promoted brands in 2008 grew 41% compared to 2007 including products: Tridural(TM), Twinject®, Plan B®, Pennsaid®, Metadol®, Seasonale(TM), Testim® and Trelstar®

- EBITDA(1) in 2008 increased 46% to a record $29.0 million compared to $19.9 million in 2007

- Signed an agreement with GlaxoSmithKline for Dexedrine® and marked the beginning of a new strategic relationship

- Signed agreement with ProStrakan Group plc (LSE:PSK - News) for Abstral® and Sancuso®

- Acquired ViRexx Medical Corp., a Canadian-based development-stage biotech company

- Entered a distribution agreement with Mission Pharmacal for Urocit-K® for kidney stone treatment

"We have just closed our 13th consecutive year of record revenues and have built a diversified specialty pharma business that is dynamic, proven and high performing in all respects. Indeed, our key promoted products revenues increased over 40% in 2008 and our financial investment in new products was the largest in our corporate history. This expansion of our marketed portfolio and pipeline has been accomplished with exciting, medically important therapeutics that have the potential to drive strong, organic growth for the foreseeable future. We expect Paladin to breakthrough a significant Canadian business threshold in 2009 and become a $100 million company," said Jonathan Ross Goodman, President and CEO of Paladin Labs.

Financial Results

Revenues for the fourth quarter of 2008 increased 30% to a record $23.1 million compared to $17.7 million in the fourth quarter of 2007. Revenues from the Company's key promoted brands including: Tridural(TM), Twinject®, Plan B®, Pennsaid®, Metadol®, Seasonale(TM), Testim® and Trelstar® increased by 22% in the fourth quarter of 2008 compared to the same period a year ago. For the year ended December 31, 2008, revenues increased 31% to a record $82.7 million compared to $62.9 million in 2007.

EBITDA(1) for the fourth quarter in 2008 increased to $7.4 million compared to EBITDA(1) of $4.9 million in the fourth quarter 2007. For the year ended December 31, 2008, EBITDA(1) increased to a record $29.0 million compared to $19.9 million in 2007.

Net income before extraordinary gain for the fourth quarter 2008 was $2.0 million or $0.14 per fully diluted share compared to the same period in 2007 of $1.0 million or $0.07 per diluted share. Net income for the fourth quarter was $6.1 million or $0.41 per fully diluted share compared to net income of $1.0 million or $0.07 per fully diluted share in 2007. Net income before extraordinary gain for the year ended December 31, 2008 was $9.7 million or $0.65 per fully diluted share compared to $4.2 million or $0.27 per fully diluted share in 2007. Net income for the year ended December 31, 2008 was a record $13.8 million or $0.92 per fully diluted share, compared to net income of $9.0 million or $0.59 per fully diluted share in 2007.

Selling and marketing expense for the fourth quarter of 2008 decreased to $5.5 million compared to $7.4 million in the fourth quarter of 2007. Selling and marketing expense for the year ended December 31, 2008 remained constant at $22 million compared to 2007.

Amortization expense for the fourth quarter 2008 increased slightly to $3.4 million from $3.2 million in the corresponding period a year ago. For the twelve-month period ended December 31, 2008, amortization expense increased slightly to $12.6 million from $12.5 million in 2007.

As at December 31 2008, Paladin's cash, cash equivalents and investments in marketable securities totaled $21.3 million. From this strong cash position, Paladin continues to pursue product acquisition opportunities.

Financial Outlook

In 2009, Paladin expects to generate at least $100 million in revenue. This forecast excludes the impact of acquisitions that may be made by the Company between now and the end of 2009.

Conference Call Notice

Paladin will host a conference call to discuss its fourth quarter results today at 10:00 a.m. EST. The dial-in number for the conference call is 1-800-732-0232 or 416-644-3419. The call will be audio-cast live and archived for 31 days at www.paladinlabs.com.

(1) EBITDA (earnings before interest, taxes, depreciation and amortization) does not have any standardized meaning under Canadian Generally Accepted Accounting Principles ("GAAP") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest expense, taxes, amortization, and unusual items; such as write-downs and gains (losses) on intellectual property and investments. EBITDA is calculated and presented consistently from period to period and agrees, on a consolidated basis, with the amount disclosed as "Earnings before under noted items" on the consolidated statement of income. The Company believes EBITDA to be an important measurement that allows it to assess the operating performance of its ongoing business on a consistent basis without the impact of amortization expenses. The Company excludes amortization expenses because their level depends substantially on non-operating factors such as the historical cost of intangible and capital assets. The Company's method for calculating EBITDA may differ from that used by other issuers and, accordingly, this measure may not be comparable to EBITDA used by other issuers.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused Canadian national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.

gruss macos

[Macos]

Press Release Source: Paladin Labs Inc.
Paladin Announces Normal Course Issuer Bid and Automatic Share Purchase Plan
Friday February 27, 2009, 8:00 am EST
Yahoo! Buzz Print MONTREAL, CANADA--(Marketwire - Feb. 27, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, today announced that it has received regulatory approval from the Toronto Stock Exchange (the "TSX") to carry out a normal course issuer bid. Paladin has been authorized to purchase up to 811,548 of its common shares, or approximately 10% of its public float of 8,115,483 common shares as at February 18, 2009, in the twelve-month period following the bid's effective date. The average daily trading volume for the 6-month period preceding February 1, 2009 is 17,755 shares. In accordance with Toronto Stock Exchange Staff Notice 2008-0005 dated November 3, 2008 and until March 31, 2009 (unless extended), a maximum daily repurchase of 50% of this average may be made, representing 8,877 shares. Thereafter, the maximum daily purchase will be 25% of this average, representing 4,438 shares. As at February 18, 2009, Paladin had 14,926,446 common shares issued and outstanding.

The number of shares purchased during 2008 pursuant to the normal course issuer bid was 99,525 at an average price per common share of $10.47.

Purchases under the bid, to be made through the facilities of the TSX only in accordance with the TSX's requirements, may commence on March 3, 2009 and will terminate on March 2, 2010, or on such earlier date as Paladin may complete its purchases pursuant to the notice of intention to make a normal course issuer bid filed with the TSX. For any particular trade, the Corporation will not purchase common shares at a price higher than the price of the immediately preceding trade on the open market by independent parties. The common shares that the Corporation intends to acquire pursuant to the bid will be cancelled.

Paladin also announced that it has renewed an automatic share purchase plan with a broker in order to facilitate repurchases of its common shares under its normal course issuer bid. Under Paladin's automatic share purchase plan, Paladin's broker may repurchase shares under the normal course issuer bid at any time including, without limitation, when Paladin would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods. Purchases will be made by Paladin's broker based upon the parameters prescribed by the TSX and applicable Canadian securities laws and the terms of the parties' written agreement. The automatic share purchase plan has been reviewed by the TSX. The automatic share purchase plan will be renewed effective as of March 3, 2009.

The Board of Directors of Paladin has concluded that the market price of Paladin's common shares, from time to time, may not reflect the inherent value of the Corporation and purchases of common shares pursuant to the bid may represent an appropriate and desirable use of the Corporation's funds.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Corporation's web site at www.paladinlabs.com.

This news release contains forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Corporation considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Corporation and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Corporation's Annual Information Form for the year ended December 31, 2007. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Corporation's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.

Contact:
Samira Sakhia
Paladin Labs Inc.
Chief Financial Officer
514-669-5367
514-344-4675 (FAX)
[e-mail]
www.paladinlabs.com

[Macos]

Paladin to Present at BioFinance 2009 in Toronto
Wednesday April 22, 2009, 4:04 pm EDT
Buzz up! Print MONTREAL, CANADA--(Marketwire - April 22, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, announced today that Joseph Walewicz, Vice President, Special Projects will present a corporate update at BioFinance 2009 on Wednesday, April 29, 2009 at 11:30 a.m. ET in room Trinity IV of the Toronto Marriott Eaton Centre. A copy of the presentation will be available at www.paladinlabs.com.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2008. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com

Contact:
Samira Sakhia, Chief Financial Officer
Paladin Labs Inc.
514-669-5367
514-344-4675 (FAX)
[e-mail]
www.paladinlabs.com
EmailIM Bookmar

[Macos]

Zahlen wieder Top, und ne neue Partnerschaft!

First Quarter Highlights

- Revenues reached $25.8 million, an increase of 53% versus last year.

- EBITDA(1) reached $11.0 million, a 103% increase over the same period last year.

- Entered into a distribution agreement under which Mission Pharmacal Company granted Paladin the exclusive Canadian rights to market and sell Urocit-K®.

- Filed a new drug submission for Trelstar® 6 month, a slow release, injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer.

"We are very pleased with the continued strength of the business, with our promoted products, international business and new product acquisitions all driving growth. More importantly, this strong growth in revenues was outpaced by a doubling of our EBITDA, demonstrating the leverage to our business and providing further cash to reinvest in our business. Our product portfolio is diverse, with more than sixty products worldwide, and our top 5 products represent under 50% of sales. We remain on track to achieve more than $100 million in revenues for 2009 with our current portfolio, and our team is busy identifying potential new deals to drive further growth." said Jonathan Ross Goodman, President and CEO of Paladin Labs.

Financial Results

Revenue for the first quarter of 2009 increased 53% or $9.0 million to $25.8 million, compared to $16.8 million in the first quarter of 2008. This increase is due to the acquisition and launch of Dexedrine® and the strong performance from the Company's key promoted products, including TriduralTM, Twinject®, SeasonaleTM, Plan B®, Pennsaid®, Metadol®, Trelstar®, and Testim® which combined increased by 11% in the first quarter of 2009 compared to the corresponding period a year ago.

First quarter 2009 earnings before interest expense, taxes, amortization, and unusual items (EBITDA(1)) increased 103% to $11.0 million, compared to EBITDA(1) of $5.4 million in the first quarter of 2008.

Net income for the quarter was $3.1 million or $0.20 per fully diluted share, compared to net income of $1.5 million or $0.10 per fully diluted share in the first quarter a year ago.

At March 31, 2009, Paladin's cash, cash equivalents and investments in marketable securities totalled $32.5 million. From this strong cash position, Paladin continues to pursue product acquisition and development opportunities.


Press Release Source: Paladin Labs Inc.
Paladin Labs and Isotechnika Inc. Form Partnership for Commercialization of Voclosporin
On Thursday May 7, 2009, 7:02 am EDT
Buzz up! Print MONTREAL, QUEBEC--(Marketwire - May 7, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with Isotechnika Inc. (TSX: ISA - News) for the commercialization of voclosporin, Isotechnika's next-generation calcineurin inhibitor, in Canada, Mexico, Central & South America, Israel and South Africa ("Territory").

Under this partnership, Paladin will pay $7 million cash and provide committed R&D funding of $4.35 million to further develop voclosporin. In addition, Paladin will own 19% of a new company called Isotechnika Pharma Inc., a public company that will continue the development of voclosporin. Isotechnika Pharma will be entitled to royalties on Paladin's sales in the Territory, and Paladin will receive royalties on the sales of voclosporin in other markets.

"We are pleased to partner with Isotechnika for the development & commercialization of voclosporin. With positive results from a recently completed Phase III trial in psoriasis, we intend to submit voclosporin for Canadian regulatory approval by the end of 2009. We believe voclosporin will find a profitable niche treating psoriasis patients, and we are excited by the much larger market opportunity for vocolosporin in the transplant indication. We look forward to participating alongside current Isotechnika shareholders in a company that will continue to develop voclosporin for the benefit of patients and shareholders," stated Jonathan Ross Goodman, President & CEO of Paladin Labs Inc.

"We are pleased to be partnering with a company like Paladin Labs, a well-regarded commercialization partner, in important pharmaceutical markets," said Dr. Foster, President & CEO of Isotechnika. "We are pleased to be able to secure capital in such a difficult market, while retaining the rights to market voclosporin in the largest, most strategic markets, including the U.S., Europe, Japan and Asia. With this improved capital position, we are better positioned to secure a global commercialization deal for voclosporin."

"This deal provides us with another product with two indications to commercialize outside of Canada. It joins our growing international business, which now includes Impavido® (worldwide), Antizol® (worldwide), Unisom® (Canada, Australia and New Zealand), Pennsaid Plus® and another undisclosed topical pain product (Canada, South Africa, Israel, Central and South America)," added Mr. Goodman.

Over the longer term, Paladin expects that its commercialization expertise and Isotechnika's significant expertise in drug discovery and development, will together identify and acquire through Isotechnika additional late-stage clinical assets. This stands to strengthen Isotechnika's product pipeline and further increase Paladin's development portfolio for Canada and other strategic markets of interest.

In addition, as a result of this transaction Paladin's non-capital losses and investment tax credits available to offset future taxable income has increased by a minimum of $100 million.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com.

This news release contains forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2008. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.

Contact:
Samira Sakhia
Paladin Labs Inc.
Chief Financial Officer
514-669-5367
514-344-4675 (FAX)
[e-mail]

gruss Macos